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Candida pelliculosa fungemia in NICU 457susceptibility of isolates to six antifungal agents was analyzed by broth microdilution method.
Amphotericin B was given to infected infants and prophylactic fluconazole was prescribed to
the other noninfected extremely low birth weight infants during the outbreak.
Results: Thrombocytopenia (platelet counts <100 109/L) was the early laboratory finding in
four infants. One of six patients died, making overall mortality 17%. Fluconazole, voriconazole,
amphotericin B, and micafungin provided good antifungal activity. Cultures from the environ-
ment and hands of caregivers were all negative. Molecular studies indicated the outbreak as
caused by a single strain. The outbreak was controlled by strict hand washing, cohort infected
patients, confined physicians and nurses to take care of patients, prophylactic fluconazole to
uninfected neonates, and proper management of human milk.
Conclusion: The study demonstrated the clinical importance of emerged non-albicans Candida
species in NICU. For unusual pathogen isolated from immunocompromised hosts, more atten-
tion should be paid to monitor the possibility of an outbreak.
Copyright ª 2012, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Invasive fungal infection is the third most common cause of
late-onset sepsis in very low birth weight (VLBW) infants,1
a critical issue in neonatology over the last 20 years.
Candida spp. account for most invasive fungal infection in
VLBW infants in the neonatal intensive care unit (NICU) and
are associated with high mortality rate, significant
morbidity, prolonged hospital course, and neuro-
developmental impairment in later life.1e3 Risk factors
related to invasive Candida infection include low birth
weight and gestational age, broad-spectrum antibiotics,
presence of central vascular access, prolonged total
parenteral nutrition, and colonization of Candida spp. on
skin and mucosal surfaces.2,3 Candida albicans and C par-
apsilosis account for most of invasive fungal infection4,5;
recent studies in this area aim at preventing colonization by
Candida species, using prophylactic antimicrobials in VLBW
infants.6
Increasing numbers of reports associate nosocomial
fungal infections with unusual Candida species. Candida
pelliculosa, also known as Hansenula anomala, a yeast
mainly found in plants, fruits, and oil, was first described
as causative in an NICU outbreak of fungemia in 1986,7
with sporadic events related to immunocompromised
patients8e11 and outbreaks12e16 reported since. This study
probes such an outbreak caused by this rare pathogen, C
pelliculosa, in a tertiary NICU of China Medical University
Hospital (CMUH) in Taiwan.
Methods
Hospital
CMUH is a 1700-bed tertiary-care teaching hospital located
in central Taiwan. Its NICU, with a capacity of 30 beds,
provides tertiary care for critical newborns; most are
premature infants or those with respiratory distress.
Definitions and study design
Cases were defined as those patients with at least one
blood culture positive for C pelliculosa. Neonates weredefined as those patients aged 28 days or younger at the
onset of fungemia. Preterm birth was defined as birth that
occurred before 37 weeks of gestation. Medical records
were reviewed regarding demographic and clinical data for
assessing potential risk factors of fungus infection: e.g.,
younger gestational age, low birth weight, previous use of
broad-spectrum antibiotics, peripherally inserted central
catheter (PICC), endotracheal tube (ETT), nasal-continuous
positive airway pressure (N-CPAP), usage of total parenteral
nutrition (TPN). Amphotericin B was given intravenously to
all infected infants, with prophylactic fluconazole given
intravenously to the remaining noninfected extremely low
birth weight infants during this outbreak.
Outbreak investigation
From February 4 to March 19, 2009, six preterm infants had
documented C pelliculosa fungemia. Time span between
identification of first and second patients was 24 days.
Epidemiological investigation proceeded immediately on
March 14, 2009, when a third case was confirmed 33 days
after the first. Multiple surveillance surface cultures were
performed on infected and noninfected neonates. We
collected one of each culture sample from the mouth and
anus of VLBW infants hospitalized from March 14 to March
31, 2009, during the outbreak. Environmental samples were
obtained from patients’ bedding, incubators, sinks, bottle
warmers, tops of trolleys, air ducts, respiratory
care equipment, Hibisol used for cleaning hands in the
NICU, alcohol used for sterile performance, outer and inner
surface of the refrigerator for storing breast milk, and 14
samples from breast milk fed to infants during this period.
A total of 62 swabs were collected from inanimate
environmental sources. Hand samples of NICU staff
members (three physicians and 26 nurses) were obtained
for culture.
Microbiological investigation
During the outbreak, all patients with sepsis had at least
one blood culture obtained for examination. Blood samples
were drawn from a peripheral vein using aseptic techniques
and cultures were performed with automated Bactec 9240
458 H.-C. Lin et al.(Becton Dickinson, Cockeysville, MD, USA). All 10 strains of
C pelliculosa from six cases were confirmed according to
API-32C and Mini API system.
Antifungal susceptibility testing
Antifungal agents tested were fluconazole (Pfizer, Inc., New
York, NY, USA), itraconazole (Janssen Pharmaceuticals,
Titusville, NJ, USA), voriconazole (Pfizer, Inc.), amphoter-
icin B (Sigma, St Louis, MO, USA), caspofungin (Merck & Co.,
Inc., Whitehouse Station, NJ, USA) and micafungin (Astellas
Pharma, Inc., Deerfield, IL, USA). Susceptibility testing of all
clinical isolates was conducted via broth microdilution
method described by the Clinical and Laboratory Standards
Institute (CLSI).17 All minimum inhibitory concentrations
(MICs) were determined spectrophotometrically (530 nm)
after incubation for 48 hours. To categorize isolates as
susceptible, CLSI interpretive criteria were employed for
fluconazole (MICs of 8 mg/mL), itraconazole (MICs of
0.125 mg/mL), voriconazole (MICs of 1 mg/mL), caspofungin
(MICs of 2 mg/mL), and micafungin (MICs of 2 mg/mL). A
breakpoint of MICs 1 mg/mL was assumed for amphotericin B
based on pharmacokinetic data.18,19 Candida krusei ATCC
6258, C parapsilosis ATCC 22019 and C albicans ATCC 90028
served as quality control strains.20
Molecular investigation
Genetic relatedness among 10 clinical isolates from six
patients obtained during the outbreak, as well as control
organisms (six C pelliculosa strains obtained from six
patients with fungemia from the burn unit and emergency
room during 2008), were characterized by randomly
amplified polymorphic DNA (RAPD) assay.21
DNA extraction
Isolates were grown on BAP agar plates (BBL Microbiology
Systems, Becton Dickinson). Subsequently, 3 to 5 colony
growth loops were suspended in 600 mL of TE buffer (10 mM
Tris, 1 mM EDTA, pH 8.0), then microcentrifuged briefly.
DNA was extracted with Genomic DNA Mini Kits (Geneaid,
Shijr City, Taiwan).
RAPD
This method has been described previously.21 The ampli-
fication reaction contained 1 U of Taq polymerase (Finn-
zyme, Espoo, Finland), 200 mM (each) deoxynucleoside
triphosphates (Viogene, Taiwan), and 0.2 mM (each)
primer in reaction buffer (1.5 mM MgCl2 and 50 mM KCl in
10 mM Tris-HCl, pH 8.3, 20 mL reaction volume). Five mL of
pure extraction DNA were added to 70-mL aliquots of PCR
mixture. Sequences of the RAPD primer were 50-GCA-
TATTCTCAG-30. After initial denaturation at 94C for 5
minutes, reaction mixture was run through 5 cycles of
denaturation at 95C for 45 seconds, annealing at 25C for
45 seconds, and extension at 72C for 1 minute, and 35
cycles of denaturation at 95C for 45 seconds, annealing at
45C for 45 seconds, and extension at 72C for 1 minute.
Reaction mixture was heated at 72C for 3 minutes, thencooled to 4C. Five mL of each PCR product mixture were
analyzed by gel electrophoresis on a 1% (wt/vol) agarose I
gel (BBI Biotech Research Laboratories, Inc., Gaithersburg,
MD, USA) in TBE buffer (89 mM Tris, 89 mM Boric
acid, 2 mM EDTA electrophoresis buffer, pH 8.0) at 100 V
for 30 minutes. Gels contained 50 ng of ethidium bromide
per mL.Results
Description of epidemic and characteristics of
patients
The first case of C pelliculosa fungemia was a 26-day-old
premature infant (Table 1). Hospital course before funge-
mia was complicated with Klebsiella pneumoniae sepsis;
the patient received broad spectrum antibiotics (piper-
acillin/tazobactam and teicoplanin) for two weeks. Three
days later, the patient was noted having increased
frequency of apneic episode on his 26th day of life when
using N-CPAP for apnea of prematurity and treated with
meropenem trihydrate initial (sepsis was suspected). The
antibiotic was later switched to amphotericin B after
a blood culture, available seven days after onset of
frequent apnea, yielded C pelliculosa. Upon these findings,
PICC was removed immediately.
Time span between identification of first and second
patients was 24 days. An epidemiological investigation was
conducted immediately after the third patient was identi-
fied, 33 days after the first. The total number of patients
admitted during this period (February 4 to March 19) and
treated in NICU for at least 48 hours was 54. Six patients
were diagnosed with C pelliculosa fungemia within 6 weeks,
five of them in the last 3 weeks of the outbreak. Table 1
records their demographic data and characteristics.
Median (range) gestational age and birth weight of these
infants were 28 (23 to 31) weeks and 1180 (700 to 1600) g,
respectively. Age at onset of fungemia ranged from 11 to 36
days. All six infants presented nonspecific sign as increased
frequency of apneic episodes; thrombocytopenia (platelet
counts <100 109/L) was the early laboratory finding in
four. Precipitating risk factors of fungemia included PICC, N-
CPAP, use of broad-spectrum antibiotics and TPN. These
patients received amphotericin B (1 mg/kg/day) treatment
for at least 14 days. Concomitant bacteremia occurred in
two patients, one due to K pneumoniae and the other
attributed to Burkholderia cepacia. Both survived. A patient
with gestational age of 23 weeks (Table 1) died of septic
shock and pulmonary interstitial emphysema, making over-
all mortality rate 17%. The rest had no complications upon
ophthalmologic or central nervous system assessments.Environmental investigation
Surveillance cultures from the environment (62 samples)
and hands of caregivers (29 samples) were all negative;
while one culture from a patient’s maternal breast milk
stored in the refrigerator yielded Candida spp. Cultures
from mouth and anus of neonates with or without fungemia
yielded no C pelliculosa during this period. Blood cultures
Table 1 Demographic and clinical characteristics of six premature patients with Candida pelliculosa fungemia
Patient GA
(wk)/sex
BW (g) Date of blood
culture sampling
(d/mo/y)
Age at the
time of fungemia
detected (d)
Presence of
thrombocytopeniac at
the time of fungemia
Broad spectrum
antibiotics use
before fungemia
Invasive
procedures
Treatment Concomitant
bacteremia
Outcome
1a 29/M 1200 04/02/09 27 Yes Yesd PICC, N-CPAP AmB Klebsiella
pneumoniae
Cured
11/02/09
2 28/F 1160 28/02/09 11 Yes No PICC AmB Cured
03/03/09
11/03/09
3b 23/M 700 01/03/09 36 Yes Yese PICC, ETT Fluconazole,
AmB
Died
12/03/09
4 25/M 1020 09/03/09 12 No No N-CPAP AmB Burkholderia
cepacia
Cured
14/03/09
5 28/F 1295 18/03/09 12 Yes No N-CPAP AmB Cured
6 31/F 1600 19/03/09 15 No No N-CPAP AmB Cured
22/03/09
a Other risk factor: intravenous amino acid use.
b Other risk factors: skin wound and intravenous lipid use.
c Thrombocytopenia, defined as platelet count <100 109/L.
d Piperacillin/tazobactam, teicoplanin, meropenem trihydrate were used previously for Klebsiella pneumoniae sepsis.
e Piperacillin/tazobactam and teicoplanin were used for previously clinical sepsis.
AmBZ amphotericin B; BWZ birth weight; ETTZ endotracheal tube; FZ female; GAZ gestational age; MZmale; N-CPAPZ nasal-continuous positive airway pressure; PICCZ per-
ipherally inserted central catheter.
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Table 2 Results of antifungal drug susceptibility testing of C pelliculosa isolates from six patients
Strain from patient Fluconazole Itraconazole Voriconazole Amphotericin B Caspofungin Micafungin
1 2 2 0.125 2 2 0.5
2 2 2 0.125 1 2 0.25
3 2 2 0.125 1 2 0.5
4-1 2 2 0.125 1 2 0.25
4-2 2 2 0.125 1 2 0.5
5 4 2 0.125 1 2 0.25
6-1 2 2 0.125 1 2 0.25
6-2 2 2 0.125 2 2 0.5
Minimum inhibitory concentrations (MICs, mg/L) of different drugs after 48 hours incubation at 35C.
460 H.-C. Lin et al.from other infants in NICU who received prophylactic flu-
conazole during the outbreak were all negative.
Intervention
In order to prevent spread of infection, we isolated all
infected patients together in one section of the facility;
these were cared for by specified medical staffs (nurses and
one resident). Following the positive culture of Candida
spp. from one sample of human milk stored in our refrig-
erator (though not C pelliculosa) all human milk was dis-
carded and no longer provided to patients. Furthermore,
we modified the standard operating procedures of handling
human milk provided to patients. All medical staffers were
reminded of the importance of strict hand washing. There
have been no new cases of Candida infection since March
24, 2009.
Antifungal susceptibility testing
Table 2 plots in vitro susceptibility. Amphotericin B MICs of
six C pelliculosa isolates were 1 mg/mL; two isolates were
considered resistant to the drug with MIC of 2 mg/mL. Flu-
conazole, voriconazole, and micafungin showed good anti-
fungal activity with MICs of 2 to 4 mg/mL, <0.125 mg/mL,
and 0.25 to 0.5 mg/mL, respectively. However, low
susceptibility to itraconazole (MICs 2 mg/mL) was observed.Figure 1. Agarose gel shows amplified DNA products generatin
Candida pelliculosa strains. Profiles in Lanes AeF are control str
outbreak. Lane M represents molecular weight size reference ma
patients were identical to each other but different from most conMolecular studies
Genetic relatedness among clinical isolates was analyzed
by RAPD assay. Fig. 1 illustrates RAPD banding patterns of
16 clinical isolates of C pelliculosa: 10 clinical strains taken
during the outbreak (all from blood cultures of different
patients) and six control strains acquired from patients
visiting the emergency room (five strains) and burn unit
(one strain) in 2008. RAPD patterns of 10 isolates from the
six patients were identical to each other but different from
controls (Fig. 1).
Discussion
Despite significant improvement in neonatal care, nosoco-
mial fungemia due to Candida spp. carries high mortality
(10.2% to 43%) among VLBW infants.3,22,23 Beyond common
well-known Candida spp. that cause invasive fungal infec-
tion, such as C albicans and C parapsilosis, the clinical
importance of unusual pathogens is rising, as reported in
recent publications.24 Candida pelliculosa, also named
Hansenula anomala or Pichia anomala in former reports, is
a rare pathogen causing fungemia recently gaining impor-
tance as an opportunistic pathogen.7,12,14,15 C pelliculosa
usually grows in contaminants from industrial or pilot plant
fermentations, soil, stored grain, lakes or streams, and
fermenting fruit; neonatal and surgical intensive care unitsg in randomly amplified polymorphic DNA (RAPD) analysis of
ains; Lanes 1 to 6-2 correspond to strains isolated during the
rkers (100-bp ladder). RAPD patterns of ten isolates from six
trol strains.
Candida pelliculosa fungemia in NICU 461have seen prior outbreaks.12,14e16 Published reports aim at
identifying different strains and susceptibility to antifungal
drugs of this yeast due to its rising clinical importance.25,26
The first identified patient in this outbreak was a 26-day-
old premature male noted as having increased frequency in
apneic episodes. He was placed on N-CPAP for respiratory
support and PICC. It was thought a sporadic event; no
investigation was initiated until the third case was identi-
fied 33 days after the first. All affected patients were VLBW
infants with common risk factors; one received an ETT with
ventilator and three PICC when C pelliculosa fungemia was
confirmed (Table 1). Two cases used broad-spectrum anti-
biotics before fungemia developed.
Despite thorough investigation, we failed to trace the
source of infection. Most literature reports were not able to
identify the source of the infection,14e16,27 except for one
in which C pelliculosa was isolated from a physician’s
hands.12 Earlier reports identified C pelliculosa fungemia in
patients with severe diarrhea,28 acute pancreatitis,29
receiving an operation for duodenal perforation,30 as well
as infants undergoing abdominal surgery due to congenital
anomaly like omphalocele31 and gastric defect.13 There-
fore, route of infection might be via the gastrointestinal
tract through contaminated food.
Patients 4, 5, and 6 (Table 1) had risk factors for invasive
fungal infection (VLBW infant with N-CPAP), yet no intra-
venous route of infection when fungemia was noted. Hence
we suggest that patients acquired C pelliculosa fungemia
through damaged mucosa (e.g., N-CPAP and ETT). The six
patients were separated into four different sections of the
NICU once fungemia was identified. This indicates that the
route of transmission involves most healthcare givers and
something that might affect most NICU patients. A long
period (33 days) between the first and third cases also
suggests the possibility that C pelliculosa had emerged
from a common source in NICU.
Murphy et al reported a C pelliculosa fungemia outbreak
in Liverpool that was not eliminated until oral nystatin
prophylaxis and topical iodophor to the venipuncture site
were implemented.7 Antifungal prophylaxis with intrave-
nous fluconazole (6 mg/kg/day) has been proven to reduce
Candida colonization and the rate of invasive candidiasis in
VLBW infants.3 During this outbreak, we prescribed
prophylactic fluconazole (6 mg/kg/dose, intravenous,
every other day), as suggested by previous reports to every
VLBW infant admitting to NICU; this seemed to be an
effective method when dealing with such an unusual
pathogen. After prophylactic fluconazole use, no further C
pelliculosa fungemia or colonization were detected among
other noninfected patients during the outbreak.
All C pelliculosa strains from our patients showed good
susceptibility to fluconazole, voriconazole, and micafungin,
but not to itraconazole. These results are similar to those of
Ribeiro da Matta et al,25 who reported in vitro susceptibility
of 58 P anomala isolates to five antifungal drugs, plus low
susceptibility to itraconazole. Fluconazole, voriconazole,
amphotericin B, and caspofungin showed favorable anti-
fungal activity,25 most C pelliculosa fungemia patients
treated effectively with amphotericin B with or without 5-
flucytosine or fluconazole.10e13,16 Barchiesi et al reported
46 C pelliculosa strains isolated from 37 patients as
susceptible in vitro to amphotericin B32; all but one of ourpatients were also treated successfully with it. The fatal
patient’s isolate was sensitive to amphotericin B with MIC
of 1 mg/mL; those with MIC 2 mg/mL isolates survived.
There is still no consensus on breakpoints for amphotericin
B therapy in C pelliculosa fungemia, although amphotericin
B seems optimal for such infections.32 Breakthrough fun-
gemias have been reported in immunocompromised
patients receiving prophylaxis with fluconazole.33 With
limited data on voriconazole and micafungin treatment of
C pelliculosa infection, our study revealed promising results
with these agents in treating C pelliculosa fungemia
in neonates. A recent study showed that micafungin is
tolerated in young infants with adequate antimicrobial
coverage of central nervous system caused by candida
infection.34
This report highlights clinical importance of emerging
non-albicans Candida species in the NICU. When dealing
with this unusual pathogen, unfamiliarity with it impedes
identification of the source and control of transmission.
Fungal infections in neonates presented various symptoms;
we were forced to treat fungemia empirically, based on
clinical suspicion and risk factors. All six infants manifested
nonspecific clinical signs, particularly apnea; thrombocy-
topenia was the early laboratory finding in four of the
infected infants. In VLBW infants, fungal and Gram-
negative pathogens are associated with lower platelet
count and prolonged thrombocytopenia compared with
Gram-positive pathogens.35
One of the six infected infants died 12 days after onset
of fungemia, and the other five had normal neurologic
findings at discharge. Murphy et al reported the first
outbreak in 1986, and two of eight preterm babies with
gestational age 24 to 31 weeks died.7 An outbreak in
a nursery reported four neonates with birth weight 1300 to
4010 g, all improving after amphotericin B treatment with
or without flucytosine.15 A mortality rate of 41.2% was re-
ported in an outbreak at a Brazilian pediatric intensive care
unit.16 This opportunistic pathogen usually infects immu-
nocompromised patients (including preterm infants) and
might cause high mortality without prompt treatment.
Tracing the outbreak history, the first episode of C pel-
liculosa fungemia occurred 24 and 25 days before the
second and third cases. Our probe started after the third
case appeared. Molecular study (RAPD) shows the same
pattern, hinting that it could originate from the same
pathogen. The limitation of this study was that we could
not determine infection source, although one human milk
sample yielded Candida spp. This outbreak was controlled
after applying infection control measures: strict hand
washing, prompt handling of human milk, and isolating
infected patients. Additionally, reassigning physician and
nurses caring for these patients is critical to outbreak
control. When an unusual pathogen was isolated from
inpatients, especially from immunocompromised hosts,
more attention should be paid to monitor the possibility of
an outbreak.Conflicts of interest
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